Moreover, the study by Ranibar S et al. (Ranjbar et al., 2019) used compounds derived from 5-oxo-hexahydroquinoline that they named D6, D5, and D3 (which have 3-chlorophenyl, 2,3-dichlorophenyl and 4-chlorophenyl substituents in the C4 position of the 5-oxo-hexahydroquinoline core) these compounds inhibit P-gp, MRP1, and BCRP, respectively; causing a reversal of drug resistance (Doxorubicin, mitoxantrone) at concentrations of 1–10 μM, in human uterine sarcoma cells (MES-SA) sensitive and resistant to drugs with P-gp overexpression. This evidence concerns the gene PGP and uterine corpus sarcoma.